Journal
CLINICAL SCIENCE
Volume 118, Issue 11-12, Pages 717-725Publisher
PORTLAND PRESS LTD
DOI: 10.1042/CS20090537
Keywords
anterior gradient protein 2 (AGR2); biomarker; CA125; ELISA; ovarian cancer
Categories
Funding
- Healthlinx Ltd
- National Health and Medical Research Council of Australia
- U.K. Higher Education Innovation Fund through the Genetic Innovation Network
- UK North West Development Agency
- Medical Research Council [G0801447] Funding Source: researchfish
- MRC [G0801447] Funding Source: UKRI
Ask authors/readers for more resources
Ovarian cancer is often asymptomatic and is diagnosed at an advanced stage with poor survival rates, thus there is an urgent need to develop biomarkers for earlier detection of ovarian cancer. In the present study, we demonstrate for the first time that the previously reported metastasis-inducing protein AGR2 (anterior gradient protein 2) can be detected in the blood of ovarian cancer patients. Using a newly developed ELISA, we show significantly increased concentrations of AGR2 protein in plasma from cancer patients relative to normal controls. Plasma AGR2 concentrations were highest in stages II and III ovarian cancer patients and were similarly elevated in patients with both serous and non-serous tumours. The identification of elevated plasma concentrations of AGR2 may provide a useful biomarker to aid in the discrimination of normal and ovarian cancer patients particularly when used in combination with CA125.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available